title: Radionuclide therapy of hepatocellular carcinoma.
abstract: Hepatocellular carcinoma (HCC) is a malignant tumour of the hepatocyte. It is a common malignancy worldwide and causes almost half a million deaths annually. Asia is a high risk area. Although surgery (hepatectomy or liver transplantation) is the main form of curative treatment, the majority of patients are not eligible for surgery due to extent of tumour and dysfunction of liver. Radiopharmaceuticals used for transarterial treatment of HCC were Yttrium-90 microspheres, Iodine-131 lipiodol, Rhenium-188 lipiodol, and Holmium-166 Chitosan complex. Yittrium-90 microspheres are glass or resin microspheres of mean sphere diameter of 20 to 30 micrometre. The activity administered was about 4 GBq. Reported response rate was about 20%, and median survival was 54 weeks. On inoperable tumours, reported objective response of I-131 lipiodol was 40 to 70%, and median survival was six to nine months. It showed efficacy similar to TACE. In adjuvant treatment following curative resection of HCC, reported three year survival was 86% compared with 46% for the control group. The administered activity in both adjuvant and inoperable HCC was about 2 GBq (55 mCi). Rhenium-188 lipiodol is a new radioconjugate, and using it we treated 70 patients with inoperable HCC. This treatment was a part of a multi-centre trial sponsored by the International Atomic Energy Agency. Partial response was obtained in 17% of cases, while 49% had stable disease at three months, and 34% showed disease progression. In terms of survival, 19% survived one year, 60% for six months, and 90% for three months. The mean activity was about 4.6 GBq (124 mCi). This method was safe and free from adverse effects.
authors: Nuclear Medicine and PET/CT Centre, Subang Jaya Medical Centre, Subang Jaya, Selangor, Malaysia.
authors: Fx
authors: F
authors: Sundram
references: Cancer. 1993 Dec 1;72(11):3210-5
references: 8242543
references: Cancer. 1987 Sep 15;60(6):1400-11
references: 3040216
references: J Nucl Med. 2000 Oct;41(10):1673-81
references: 11037997
references: Ann Acad Med Singap. 2002 May;31(3):382-6
references: 12061301
references: Gastroenterology. 2004 Nov;127(5 Suppl 1):S194-205
references: 15508085
references: Hepatology. 2003 Feb;37(2):429-42
references: 12540794
references: Br J Cancer. 1994 Nov;70(5):994-9
references: 7947110
references: Cancer Biother Radiopharm. 2000 Feb;15(1):65-70
references: 10740654
references: Radiology. 2002 Jul;224(1):47-54
references: 12091661
references: Cancer Res. 1987 Sep 15;47(18):4967-72
references: 3040235
references: Hepatology. 1997 Nov;26(5):1156-61
references: 9362356
references: J Nucl Med. 1994 Nov;35(11):1782-7
references: 7525901
references: Int J Radiat Oncol Biol Phys. 1998 Feb 1;40(3):583-92
references: 9486608
references: Cancer. 1992 Feb 15;69(4):925-9
references: 1310435
references: J Nucl Med. 1994 Oct;35(10):1637-44
references: 7931662
references: Cancer. 1992 Nov 1;70(9):2250-4
references: 1327493
references: Lancet. 1998 Jul 4;352(9121):17-20
references: 9800740
references: Radiology. 1999 Mar;210(3):655-61
references: 10207464
references: J Nucl Med. 1996 Jun;37(6):958-63
references: 8683320
references: Nucl Med Commun. 2002 Mar;23(3):237-42
references: 11891481
references: Nucl Med Biol. 2001 Feb;28(2):197-204
references: 11295430
references: J Nucl Med. 1994 Aug;35(8):1313-8
references: 7519259
references: Arch Surg. 2000 Nov;135(11):1298-300
references: 11074884
references: Arch Surg. 2002 Apr;137(4):422-6; discussion 427
references: 11926946
references: Lancet. 1999 Mar 6;353(9155):797-801
references: 10459961
references: World J Gastroenterol. 1999 Dec;5(6):492-505
references: 11819498
references: Cancer. 1995 Dec 1;76(11):2202-10
references: 8635022
references: Eur J Nucl Med Mol Imaging. 2004 Feb;31(2):250-7
references: 15129708
references: Am J Clin Oncol. 1994 Oct;17(5):393-5
references: 8092109
references: Eur J Nucl Med Mol Imaging. 2006 Mar;33(3):344-52
references: 16333675
references: J Nucl Med. 1984 Sep;25(9):972-7
references: 6088735